
What is claimed is:

1. Use of a compound, the compound having the structure of Formula I:



I

wherein,

E_1 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_2 is H, OH, NH_2, R, O, NHR, NR_2, SH, SR, F, Cl, Br, or I;



E_3 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_4 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;







R is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NR', and each carbon may be optionally substituted with one or more of: OH, OR', R', F, Cl, Br, I, =O, SH, SR', NH_2, NHR', $N(R')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(R')_2$ and CO_2R';




R' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

A is H, or NH_2;

D is  or  ; or

A and D form a 6 membered ring selected from the following:

 ;  ;  ;  ;  ;  ;

 ;  ; or  ;

G is CH or N;

J is S or O;

L_1 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

L_2 is O, SQ', or NQ';

L_3 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

Q is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NQ', and each carbon may be optionally substituted with one or more of: OH, OQ', Q', F, Cl, Br, I, =O, SH, SQ', NH_2, NHQ', $N(Q')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Q')_2$ and CO_2Q';

Q' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

M_1 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_2 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_3 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M4 is OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

T is H, or a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NT', and each carbon may be optionally substituted with one or more of: OH, OT', T', F, Cl, Br, I, =O, SH, ST', NH_2, NHT', $N(T')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(T')_2$ and CO_2T';

T' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

X_1 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_2 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;


X_3 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I; and

Z is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NZ', and each carbon may be optionally substituted with one or more of: OH, OZ', Z', F, Cl, Br, I, =O, SH, SZ', NH_2, NHZ', $N(Z')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Z')_2$ and CO_2Z'; and

Z' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

for the treatment of fibrotic disease.

2. Use of a compound, the compound having the structure of Formula I:



I

wherein,

E_1 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_2 is H, OH, NH_2, R, O, NHR, NR_2, SH, SR, F, Cl, Br, or I;


E_3 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_4 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;



R is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NR', and each carbon may be optionally substituted with one or more of: OH, OR', R', F, Cl, Br, I, =O, SH, SR', NH_2, NHR', $N(R')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(R')_2$ and CO_2R'; and

R' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

A is H, or NH_2;

D is  ; or

A and D form a 6 membered ring selected from the following:

 ; ;  ; or ;

G is CH or N;

J is S or O;

L_1 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

L_2 is O, SQ', or NQ';

L_3 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

Q is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NQ', and each carbon may be optionally substituted with one or more of: OH, OQ', Q', F, Cl, Br, I, =O, SH, SQ', NH_2, NHQ', $N(Q')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Q')_2$ and CO_2Q';

Q' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

M_1 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_2 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_3 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M4 is OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

T is H, or a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NT', and each carbon may be optionally substituted with one or more of: OH, OT', T', F, Cl, Br, I, =O, SH, ST', NH_2, NHT', $N(T')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(T')_2$ and CO_2T';

T' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

X_1 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_2 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_3 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I; and

Z is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NZ', and each carbon may be optionally substituted with one or more of: OH, OZ', Z', F, Cl, Br, I, =O, SH, SZ', NH_2, NHZ', $N(Z')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Z')_2$ and CO_2Z'; and

Z' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

for the manufacture of a medicament to treat fibrotic disease.

3. The use of claim 1 or 2, wherein the fibrotic disease is selected from one or more of the following: keloid; hypertrophic scaring; pulmonary fibrosis; kidney fibrosis; liver cirrhosis; chronic inflammation of tunica albugenia (CITA); endomyocardial fibrosis; mediastinal fibrosis; myelofibrosis; retroperitoneal fibrosis; progressive massive fibrosis; nephrogenic systemic fibrosis; Crohn's disease; old myocardial infarction; scleroderma; systemic sclerosis; uterine fibroids; and restenosis.

4. The use of claim 1, 2 or 3, wherein,

Q is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

R is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

T is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

Z is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

5. The use of any one of claims 1-4, wherein,

Q' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

R' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

T' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

Z' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

6. The use of any one of claims 1-5, wherein



E_1 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_2 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;




E_3 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_4 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

A is H or NH_2;

D is  or  ; or

A and D form a 6 membered ring selected from the following:

 ;  ; or  ;

G is CH or N;

L_1 is OH, NH_2, or SH;

M_1 is H, OH, NH_2, SH, F, Cl, Br, or I;

M4 is OH, NH_2, SH, F, Cl, Br, or I; and

X_1 is H, OH, NH_2, SH, F, Cl, Br, or I

7. The use of any one of claims 1-6, wherein


E_1 is H, OH, NH_2, OCH_3, or CH_3;

E_2 is H, OH, NH_2, OCH_3, or CH_3;



E_3 is H, OH, NH_2, OCH_3, or CH_3;

E_4 is H, OH, NH_2, OCH_3, or CH_3;

A is H or NH_2;

D is  ; or

A and D form a 6 membered ring selected from the following:

 ; or  ;

G is CH or N;

L_1 is OH or NH_2; and

M_1 is H, OH, or NH_2.

8. The use of any one of claims 1-7, wherein


E_1 is H, OH, NH_2, OCH_3, or CH_3;

E_2 is H, OH, NH_2, OCH_3, or CH_3;


E_3 is H, OH, NH_2, OCH_3, or CH_3;

E_4 is H, OH, NH_2, OCH_3, or CH_3;

A is H, or NH_2; and

D is ; or

A and D form a 6 membered ring having the following structure:

.

9. The use of any one of claims 1-8, wherein


E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;


E_3 is H, OH, or NH_2;

E_4 is H, OH, or NH_2;


A is H, or NH_2; and

D is ; or

A and D form a 6 membered ring having the following structure:


.

10. The use of any one of claims 1-9, wherein the compound has the structure of Formula II:



II.

11. The use of any one of claims 1-9, wherein the compound has the structure of Formula III:



III.

12. The use of claim 11, wherein L_1 is OH or NH_2.

13. The use of claim 11, wherein L_1 is OH.

14. The use of any one of claims 1-13, wherein
E_1 is H or OH;
E_2 is H, OH, or NH_2;
E_3 is H, OH, or NH_2; and
E_4 is H, OH, or NH_2.

15. The use of any one of claims 1-13, wherein
E_1 is H, OH, or NH_2;
E_2 is H or OH;
E_3 is H, OH, or NH_2; and
E_4 is H, OH, or NH_2.

16. The use of any one of claims 1-13, wherein
E_1 is H, OH, or NH_2;
E_2 is H, OH, or NH_2;
E_3 is H or OH; and
E_4 is H, OH, or NH_2.

17. The use of any one of claims 1-13, wherein
E_1 is H, OH, or NH_2;
E_2 is H, OH, or NH_2;
E_3 is H or OH; and
E_4 is H or NH_2.

18. The use of any one of claims 1-13, wherein









E_1 is H or OH;

E_2 is H or OH;








E_3 is H or OH; and

E_4 is H or NH_2.


19. The use of any one of claims 1-18, wherein the compound is selected from one or more of the following:


;

;

;

;

;

;

; and


20. The use of any one of claims 1-18, wherein the compound is selected from one or more of the following:


;

;

;

;

;

; and

.

21. A method of treating fibrotic disease, the method comprising administering to a mammalian cell a compound or pharmaceutically acceptable salt thereof, the compound having the structure of Formula I:



I

wherein,

E_1 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_2 is H, OH, NH_2, R, O, NHR, NR_2, SH, SR, F, Cl, Br, or I;



E_3 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_4 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;







R is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NR', and each carbon may be optionally substituted with one or more of: OH, OR', R', F, Cl, Br, I, =O, SH, SR', NH_2, NHR', $N(R')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(R')_2$ and CO_2R';




R' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

A is H, or NH_2;

D is  or  ; or

A and D form a 6 membered ring selected from the following:

 ;  ;  ;  ;  ;  ;

 ;  ; or  ;

G is CH or N;

J is S or O;

L_1 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

L_2 is O, SQ', or NQ';

L_3 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

Q is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NQ', and each carbon may be optionally substituted with one or more of: OH, OQ', Q', F, Cl, Br, I, =O, SH, SQ', NH_2, NHQ', $N(Q')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Q')_2$ and CO_2Q';

Q' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

M_1 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_2 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_3 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M4 is OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

T is H, or a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NT', and each carbon may be optionally substituted with one or more of: OH, OT', T', F, Cl, Br, I, =O, SH, ST', NH_2, NHT', $N(T')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(T')_2$ and CO_2T';

T' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

X_1 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;


X_2 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_3 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I; and

Z is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NZ', and each carbon may be optionally substituted with one or more of: OH, OZ', Z', F, Cl, Br, I, =O, SH, SZ', NH_2, NHZ', $N(Z')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Z')_2$ and CO_2Z'; and

Z' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

22. A method of treating fibrotic disease, the method comprising administering to a subject in need thereof, a compound or pharmaceutically acceptable salt thereof, the compound having the structure of Formula I:



I

wherein,

E_1 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_2 is H, OH, NH_2, R, O, NHR, NR_2, SH, SR, F, Cl, Br, or I;



E_3 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_4 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;







R is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NR', and each carbon may be optionally substituted with one or more of: OH, OR', R', F, Cl, Br, I, =O, SH, SR', NH_2, NHR', $N(R')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(R')_2$ and CO_2R';




R' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

A is H, or NH_2;

D is  or  ; or

A and D form a 6 membered ring selected from the following:

 ;  ;  ;  ;  ;  ;

 ;  ; or  ;

G is CH or N;

J is S or O;

L_1 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

L_2 is O, SQ', or NQ';

L_3 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

Q is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NQ', and each carbon may be optionally substituted with one or more of: OH, OQ', Q', F, Cl, Br, I, =O, SH, SQ', NH_2, NHQ', $N(Q')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Q')_2$ and CO_2Q';

Q' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

M_1 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_2 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_3 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M4 is OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

T is H, or a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NT', and each carbon may be optionally substituted with one or more of: OH, OT', T', F, Cl, Br, I, =O, SH, ST', NH_2, NHT', $N(T')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(T')_2$ and CO_2T';

T' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

X_1 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_2 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_3 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I; and

Z is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NZ', and each carbon may be optionally substituted with one or more of: OH, OZ', Z', F, Cl, Br, I, =O, SH, SZ', NH_2, NHZ', $N(Z')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Z')_2$ and CO_2Z'; and

Z' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

23. The method of claim 21 or 22, wherein the fibrotic disease is selected from one or more of the following: keloid; hypertrophic scaring; pulmonary fibrosis; kidney fibrosis; liver cirrhosis; chronic inflammation of tunica albugenia (CITA); endomyocardial fibrosis; mediastinal fibrosis; myelofibrosis; retroperitoneal fibrosis; progressive massive fibrosis; nephrogenic systemic fibrosis; Crohn's disease; old myocardial infarction; scleroderma; systemic sclerosis; uterine fibroids; and restenosis.

24. The method of claim 21, 22 or 23, wherein,

Q is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

R is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

T is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

Z is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

25. The method of any one of claims 21-24, wherein,

Q' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

R' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

T' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

Z' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

26. The method of any one of claims 21-25, wherein



E_1 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_2 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;




E_3 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_4 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

A is H or NH_2;

D is  or  ; or

A and D form a 6 membered ring selected from the following:

 ;  ; or  ;

G is CH or N;

L_1 is OH, NH_2, or SH;

M_1 is H, OH, NH_2, SH, F, Cl, Br, or I;

M4 is OH, NH_2, SH, F, Cl, Br, or I; and

X_1 is H, OH, NH_2, SH, F, Cl, Br, or I.

27. The method of any one of claims 21-26, wherein


E_1 is H, OH, NH_2, OCH_3, or CH_3;

E_2 is H, OH, NH_2, OCH_3, or CH_3;



E_3 is H, OH, NH_2, OCH_3, or CH_3;

E_4 is H, OH, NH_2, OCH_3, or CH_3;

A is H or NH_2;

D is  ; or

A and D form a 6 membered ring selected from the following:

 ; or  ;

G is CH or N;

L_1 is OH or NH_2; and

M_1 is H, OH, or NH_2.

28. The method of any one of claims 21-27, wherein


E_1 is H, OH, NH_2, OCH_3, or CH_3;

E_2 is H, OH, NH_2, OCH_3, or CH_3;


E_3 is H, OH, NH_2, OCH_3, or CH_3;

E_4 is H, OH, NH_2, OCH_3, or CH_3;

A is H, or NH_2; and

D is  ; or

A and D form a 6 membered ring having the following structure:

 .

29. The method of any one of claims 21-28, wherein


E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;


E_3 is H, OH, or NH_2;

E_4 is H, OH, or NH_2;


A is H, or NH_2; and

D is  ; or

A and D form a 6 membered ring having the following structure:


 .

30. The method of any one of claims 21-29, wherein the compound has the structure of Formula II:



II.

31. The method of any one of claims 21-29, wherein the compound has the structure of Formula III:



III.

32. The method of claim 31, wherein L_1 is OH or NH_2.

33. The method of claim 31, wherein L_1 is OH.

34. The method of any one of claims 21-33, wherein

E_1 is H or OH;

E_2 is H, OH, or NH_2;

E_3 is H, OH, or NH_2; and

E_4 is H, OH, or NH_2.

35. The method of any one of claims 21-33, wherein

E_1 is H, OH, or NH_2;

E_2 is H or OH;

E_3 is H, OH, or NH_2; and

E_4 is H, OH, or NH_2.

36. The method of any one of claims 21-33, wherein

E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;

E_3 is H or OH; and

E_4 is H, OH, or NH_2.

37. The method of any one of claims 21-33, wherein

E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;

E_3 is H or OH; and

E_4 is H or NH_2.

38. The method of any one of claims 21-33, wherein









E_1 is H or OH;

E_2 is H or OH;








E_3 is H or OH; and

E_4 is H or NH_2.


39. The method of any one of claims 21-38, wherein the compound is selected from one or more of the following:


;

;

;

;

;

;

; and


40. The method of any one of claims 21-38, wherein the compound is selected from one or more of the following:


;

;

;

;

;

; and

.

41. A pharmaceutical composition for treating fibrotic disease, the pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the compound has the structure of Formula I:



I

wherein,

E_1 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_2 is H, OH, NH_2, R, O, NHR, NR_2, SH, SR, F, Cl, Br, or I;



E_3 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_4 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;







R is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NR', and each carbon may be optionally substituted with one or more of: OH, OR', R', F, Cl, Br, I, =O, SH, SR', NH_2, NHR', $N(R')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(R')_2$ and CO_2R';




R' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

A is H, or NH_2;

D is  or  ; or

A and D form a 6 membered ring selected from the following:

 ;  ;  ;  ;  ;  ;

 ;  ; or  ;

G is CH or N;

J is S or O;

L_1 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

L_2 is O, SQ', or NQ';

L_3 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

Q is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NQ', and each carbon may be optionally substituted with one or more of: OH, OQ', Q', F, Cl, Br, I, =O, SH, SQ', NH_2, NHQ', $N(Q')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Q')_2$ and CO_2Q';

Q' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

M_1 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_2 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M_3 is H, OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

M4 is OH, NH_2, T, OT, NHT, NT_2, SH, ST, F, Cl, Br, or I;

T is H, or a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NT', and each carbon may be optionally substituted with one or more of: OH, OT', T', F, Cl, Br, I, =O, SH, ST', NH_2, NHT', $N(T')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(T')_2$ and CO_2T';

T' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

X_1 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_2 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I;

X_3 is H, OH, NH_2, Z, OZ, NHZ, NZ_2, SH, SZ, F, Cl, Br, or I; and

Z is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NZ', and each carbon may be optionally substituted with one or more of: OH, OZ', Z', F, Cl, Br, I, =O, SH, SZ', NH_2, NHZ', $N(Z')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Z')_2$ and CO_2Z'; and

Z' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

42. The pharmaceutical composition of claim 41, wherein the fibrotic disease is selected from one or more of the following: keloid; hypertrophic scaring; pulmonary fibrosis; kidney fibrosis; liver cirrhosis; chronic inflammation of tunica albugenia (CITA); endomyocardial fibrosis; mediastinal fibrosis; myelofibrosis; retroperitoneal fibrosis; progressive massive fibrosis; nephrogenic systemic fibrosis; Crohn's disease; old myocardial infarction; scleroderma; systemic sclerosis; uterine fibroids; and restenosis.

43. The pharmaceutical composition of claim 41 or 42, wherein,

Q is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

R is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

T is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

Z is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

44. The pharmaceutical composition of any one of claims 41-43, wherein,

Q' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

R' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

T' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

Z' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

45. The pharmaceutical composition of any one of claims 41-44, wherein



E_1 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_2 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;




E_3 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_4 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

A is H or NH_2;

D is  or  ; or

A and D form a 6 membered ring selected from the following:

 ;  ; or  ;

G is CH or N;

L_1 is OH, NH_2, or SH;

M_1 is H, OH, NH_2, SH, F, Cl, Br, or I;

M4 is OH, NH_2, SH, F, Cl, Br, or I; and

X_1 is H, OH, NH_2, SH, F, Cl, Br, or I.

46. The pharmaceutical composition of any one of claims 41-45, wherein


E_1 is H, OH, NH_2, OCH_3, or CH_3;

E_2 is H, OH, NH_2, OCH_3, or CH_3;



E_3 is H, OH, NH_2, OCH_3, or CH_3;

E_4 is H, OH, NH_2, OCH_3, or CH_3;

A is H or NH_2;

D is  ; or

A and D form a 6 membered ring selected from the following:

 ; or  ;

G is CH or N;

L_1 is OH or NH_2; and

M_1 is H, OH, or NH_2.

47. The pharmaceutical composition of any one of claims 41-46, wherein


E_1 is H, OH, NH_2, OCH_3, or CH_3;

E_2 is H, OH, NH_2, OCH_3, or CH_3;


E_3 is H, OH, NH_2, OCH_3, or CH_3;

E_4 is H, OH, NH_2, OCH_3, or CH_3;

A is H, or NH_2; and

D is  ; or

A and D form a 6 membered ring having the following structure:

 .

48. The pharmaceutical composition of any one of claims 41-47, wherein


E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;


E_3 is H, OH, or NH_2;

E_4 is H, OH, or NH_2;


A is H, or NH_2; and

D is  ; or

A and D form a 6 membered ring having the following structure:


 .

49. The pharmaceutical composition of any one of claims 41-48, wherein the compound has the structure of Formula II:



II.

50. The pharmaceutical composition of any one of claims 41-48, wherein the compound has the structure of Formula III:



III.

51. The pharmaceutical composition of claim 50, wherein L_1 is OH or NH_2.

52. The pharmaceutical composition of claim 50, wherein L_1 is OH.

53. The pharmaceutical composition of any one of claims 41-52, wherein

E_1 is H or OH;

E_2 is H, OH, or NH_2;

E_3 is H, OH, or NH_2; and

E_4 is H, OH, or NH_2.

54. The pharmaceutical composition of any one of claims 41-52, wherein

E_1 is H, OH, or NH_2;

E_2 is H or OH;

E_3 is H, OH, or NH_2; and

E_4 is H, OH, or NH_2.

55. The pharmaceutical composition of any one of claims 41-52, wherein

E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;

E_3 is H or OH; and

E_4 is H, OH, or NH_2.

56. The pharmaceutical composition of any one of claims 41-52, wherein

E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;

E_3 is H or OH; and

E_4 is H or NH_2.

57. The pharmaceutical composition of any one of claims 41-52, wherein









E_1 is H or OH;

E_2 is H or OH;








E_3 is H or OH; and

E_4 is H or NH_2.

58. The pharmaceutical composition of any one of claims 41-57, wherein the compound is selected from one or more of the following:


;

;

;

;

;

;

; and



59. The pharmaceutical composition of any one of claims 41-57, wherein the compound is selected from one or more of the following:


;

;

;

;

;

; and

.

60. A commercial package comprising (a) a pharmaceutical composition of any one of claims 41-59; and (b) instructions for the use thereof for treating fibrotic disease.

What is claimed is:

1. Use of a compound, the compound having the structure of Formula II or III:



wherein,

E_1 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_2 is H, OH, NH_2, R, O, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_3 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_4 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

R is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NR', and each carbon may be optionally substituted with one or more of: OH, OR', R', F, Cl, Br, I, =O, SH, SR', NH_2, NHR', $N(R')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(R')_2$ and CO_2R'; and

R' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

A is H, or NH_2**;**

L_1 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

Q is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NQ', and each carbon may be optionally substituted with one or more of: OH, OQ', Q', F, Cl, Br, I, =O, SH, SQ', NH_2, NHQ', $N(Q')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Q')_2$ and CO_2Q'; and

Q' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

for the manufacture of a medicament to treat fibrotic disease, wherein the fibrotic disease is selected from one or more of the following: keloid; hypertrophic scaring; pulmonary fibrosis; kidney fibrosis; liver cirrhosis; endomyocardial fibrosis; mediastinal fibrosis; myelofibrosis; retroperitoneal fibrosis; progressive massive fibrosis; nephrogenic systemic

fibrosis; old myocardial infarction; scleroderma; systemic sclerosis; uterine fibroids; and restenosis.

2. The use of claim 1, wherein the fibrotic disease is selected from one or more of the following: keloid; and hypertrophic scaring.

3. The use of claim 1, or 2, wherein,

Q is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

R is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

4. The use of claim 1, 2, or 3, wherein,

Q' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

R' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

5. The use of any one of claims 1-4, wherein

E_1 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_2 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_3 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_4 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

A is H or NH_2**;** or7

L_1 is OH, NH_2, or SH.

6. The use of any one of claims 1-5, wherein

E_1 is H, OH, NH_2, OCH_3, or CH_3;

E_2 is H, OH, NH_2, OCH_3, or CH_3;

E_3 is H, OH, NH_2, OCH_3, or CH_3;

E_4 is H, OH, NH_2, OCH_3, or CH_3;

A is H or NH_2**;** and

L_1 is OH or NH_2.

.

7. The use of any one of claims 1-6, wherein
E_1 is H, OH, NH_2, OCH_3, or CH_3;
E_2 is H, OH, NH_2, OCH_3, or CH_3;
E_3 is H, OH, NH_2, OCH_3, or CH_3;
E_4 is H, OH, NH_2, OCH_3, or CH_3; and
A is H, or NH_2.

8. The use of any one of claims 1-7, wherein
E_1 is H, OH, or NH_2;
E_2 is H, OH, or NH_2;
E_3 is H, OH, or NH_2;
E_4 is H, OH, or NH_2; and
A is H, or NH_2.

9. The use of any one of claims 1-8, wherein L_1 is OH or NH_2.

10. The use of any one of claims 1-9, wherein L_1 is OH.

11. The use of any one of claims 1-8 and 9-10, wherein
E_1 is H or OH;
E_2 is H, OH, or NH_2;
E_3 is H, OH, or NH_2; and
E_4 is H, OH, or NH_2.

12. The use of any one of claims 1-8 and 9-10, wherein
E_1 is H, OH, or NH_2;
E_2 is H or OH;
E_3 is H, OH, or NH_2; and
E_4 is H, OH, or NH_2.

13. The use of any one of claims 1-8 and 9-10, wherein
E_1 is H, OH, or NH_2;
E_2 is H, OH, or NH_2;

E_3 is H or OH; and

E_4 is H, OH, or NH_2.

14. The use of any one of claims 1-8 and 9-10, wherein

E_1 is H, OH, or NH_2;

E_2 is H, OH, or NH_2;

E_3 is H or OH; and

E_4 is H or NH_2.

15. The use of any one of claims 1-8 and 9-10, wherein


E_1 is H or OH;


E_2 is H or OH;


E_3 is H or OH; and


E_4 is H or NH_2.


16. The use of any one of claims 1-8 and 9-15, wherein the compound is selected from one or more of the following:





;



;


;



;


;



;


; and


17. The use of any one of claims 1-8 and 9-15, wherein the compound is selected from one or more of the following:



18. A pharmaceutical composition for use in treating fibrotic disease, the pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the compound has the structure of Formula II or III:



wherein,

E_1 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_2 is H, OH, NH_2, R, O, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_3 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

E_4 is H, OH, NH_2, R, OR, NHR, NR_2, SH, SR, F, Cl, Br, or I;

R is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon may be optionally replaced by O, S, SO, SO_2, NH, or NR', and each carbon may be optionally substituted with one or more of: OH, OR', R', F, Cl, Br, I, =O, SH, SR', NH_2, NHR', $N(R')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(R')_2$ and CO_2R'; and

R' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic;

A is H, or NH_2**;**

L_1 is OH, OQ, NH_2, NHQ, NQ_2, SH, or SQ;

Q is a 1 to 20 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic, where each carbon

may be optionally replaced by O, S, SO, SO_2, NH, or NQ', and each carbon may be optionally substituted with one or more of: OH, OQ', Q', F, Cl, Br, I, =O, SH, SQ', NH_2, NHQ', $N(Q')_2$, OSO_3H, OPO_3H_3, CO_2H, $CON(Q')_2$ and CO_2Q'; and

Q' is independently selected from the group consisting of: a one to ten carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

wherein the fibrotic disease is selected from one or more of the following: keloid; hypertrophic scaring; pulmonary fibrosis; kidney fibrosis; liver cirrhosis; endomyocardial fibrosis; mediastinal fibrosis; myelofibrosis; retroperitoneal fibrosis; progressive massive fibrosis; nephrogenic systemic fibrosis; old myocardial infarction; scleroderma; systemic sclerosis; uterine fibroids; and restenosis.

19. The pharmaceutical composition of claim 18, wherein the fibrotic disease is selected from one or more of the following: keloid; and hypertrophic scaring.

20. The pharmaceutical composition of claim 18 or 19, wherein,

Q is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

R is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

21. The pharmaceutical composition of any one of claims 18-20, wherein,

Q' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic; and

R' is a 1 to 6 carbon group that is optionally saturated, unsaturated, linear, branched linear, cyclic, branched cyclic, aromatic, partially aromatic or non aromatic.

22. The pharmaceutical composition of any one of claims 18-21, wherein

E_1 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_2 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_3 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

E_4 is H, OH, NH_2, OCH_3, CH_3, SH, F, Cl, Br, or I;

A is H or NH_2; and

L_1 is OH, NH_2, or SH.

23. The pharmaceutical composition of any one of claims 18-22, wherein
E_1 is H, OH, NH_2, OCH_3, or CH_3;
E_2 is H, OH, NH_2, OCH_3, or CH_3;
E_3 is H, OH, NH_2, OCH_3, or CH_3;
E_4 is H, OH, NH_2, OCH_3, or CH_3;
A is H or NH_2; and
L_1 is OH or NH_2.

24. The pharmaceutical composition of any one of claims 18-23, wherein
E_1 is H, OH, NH_2, OCH_3, or CH_3;
E_2 is H, OH, NH_2, OCH_3, or CH_3;
E_3 is H, OH, NH_2, OCH_3, or CH_3;
E_4 is H, OH, NH_2, OCH_3, or CH_3; and
A is H, or NH_2.

25. The pharmaceutical composition of any one of claims 18-24, wherein
E_1 is H, OH, or NH_2;
E_2 is H, OH, or NH_2;
E_3 is H, OH, or NH_2;
E_4 is H, OH, or NH_2; and
A is H, or NH_2.

26. The pharmaceutical composition of any one of claims 18-25, wherein L_1 is OH or NH_2.

27. The pharmaceutical composition of any one of claims 18-25, wherein L_1 is OH.

28. The pharmaceutical composition of any one of claims 18-25 and 26-27, wherein
E_1 is H or OH;
E_2 is H, OH, or NH_2;
E_3 is H, OH, or NH_2; and
E_4 is H, OH, or NH_2.

29. The pharmaceutical composition of any one of claims 18-25 and 26-27, wherein
E_1 is H, OH, or NH_2;









E_2 is H or OH;
E_3 is H, OH, or NH_2; and
E_4 is H, OH, or NH_2.

30. The pharmaceutical composition of any one of claims 18-25 and 26-27, wherein
E_1 is H, OH, or NH_2;
E_2 is H, OH, or NH_2;
E_3 is H or OH; and
E_4 is H, OH, or NH_2.








31. The pharmaceutical composition of any one of claims 18-25 and 26-27, wherein
E_1 is H, OH, or NH_2;
E_2 is H, OH, or NH_2;
E_3 is H or OH; and
E_4 is H or NH_2.

32. The pharmaceutical composition of any one of claims 18-25 and 26-27, wherein
E_1 is H or OH;
E_2 is H or OH;
E_3 is H or OH; and
E_4 is H or NH_2.

33. The pharmaceutical composition of any one of claims 18-25 and 26-32, wherein the compound is selected from one or more of the following:


;

;

;

;

;

;

; and


34. The pharmaceutical composition of any one of claims 18-25 and 26-32, wherein the compound is selected from one or more of the following:


;

;

;

;

;

; and

.

35. A commercial package comprising (a) a pharmaceutical composition of any one of claims 18-25 and 26-34; and (b) instructions for the use thereof for treating fibrotic disease, wherein the fibrotic disease is selected from one or more of the following: keloid; hypertrophic scaring; pulmonary fibrosis; kidney fibrosis; liver cirrhosis; endomyocardial fibrosis; mediastinal fibrosis; myelofibrosis; retroperitoneal fibrosis; progressive massive fibrosis; nephrogenic systemic fibrosis; old myocardial infarction; scleroderma; systemic sclerosis; uterine fibroids; and restenosis.